<DOC>
	<DOCNO>NCT00226954</DOCNO>
	<brief_summary>Primary : To determine duration use zoledronic acid improve Bone mineral density patient prostate cancer hormone intermittently . Secondary Objectives : To describe safety tolerability dose schedule</brief_summary>
	<brief_title>Zoledronic Acid With Intermittent Hormonal Therapy Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Patients : Who 18 year age older Who histologically document adenocarcinoma prostate Who currently receive LHRH agonist KPS great 80 % Life expectancy great 6 month Provide write consent pursuant regulatory requirement prior initiation study procedure Patients : Any patient require continuous LHRH Any patient orchiectomy Any patient painful bone metastasis Who receive chemotherapy prostate cancer Who abnormal serum creatine &gt; 2.5 Receiving investigational drug within last 28 day Severe uncontrolled infection , diabetes , cardiac disease Patients fragility fracture , hyperparathyroidism , Pagets renal osteodystrophy exclude History non compliance medical regimen unwillingness return medical visit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>